The fact that targeting of TLR7 agonists to FRβ+ TAMs/MDSCs leads to a significant reduction in tumor growth (17) suggests that FRβ+ TAMs/MDSCs are naturally immunosuppressive. This evidence concerns the gene FOLR2 and neoplasm.